About us

Our goal is to improve breast cancer treatment for all

Each year 2 million women are diagnosed with breast cancer and most will undergo some form of surgery.

Our goal is to develop technologies that allow physicians to give every one of those women a better standard of cancer care.

For each hospital that adopts our products, our hope is that more and more women with breast cancer can avoid surgery when it isn’t needed, and experience better outcomes when it is.

Our story

Endomag was founded in 2007 out of research conducted at the University College London (UCL) and the University of Houston.

We’ve grown from an academic research project into a global company with the belief that our technology can become the new standard of care across the world.

15 years into our company story, our products are now routinely used by over 1000 hospitals in more than 45 countries. Over 450,000 women will have now accessed more precise and less invasive breast cancer treatment.

Our mission is to improve breast cancer care in three ways

01

Prevent unnecessary surgery

By offering physicians new techniques that are more accurate and provide greater flexibility, we help patients avoid unnecessary surgery.

02

Improve surgical outcomes

Our aim is to give physicians the best possible tools so that patients can benefit from more precise, less invasive surgery.

03

Make treatments accessible

We’re creating greater access to a better standard of care. Unlike radioactive treatments, our technology can be accessed by any hospital.

Our mission is to improve breast cancer care in three ways

01

Prevent unnecessary surgery

By offering physicians new techniques that are more accurate and provide greater flexibility, we help patients avoid unnecessary surgery.

02

Improve surgical outcomes

Our aim is to give physicians the best possible tools so that patients can benefit from more precise, less invasive surgery.

03

Make treatments accessible

We’re creating greater access to a better standard of care. Unlike radioactive treatments, our technology can be accessed by any hospital.

Trusted by physicians and patients globally

450,000

total patients treated

1,000+

hospitals

45+

countries globally

6

continents

100+

clinical trials

Leadership team

Eric Mayes PhD, CEO

Eric Mayes, PhD

Chief Executive Officer

Andrew Shawcross PhD, COO

Andrew Shawcross, PhD

Chief Operations Officer

Quentin Harmer PhD, CTO

Quentin Harmer, PhD

Chief Technology Officer

Mathew Stephens, CMO

Mathew Stephens

Chief Marketing Officer

Rob Hincks FCCA, CFO

Rob Hincks, FCCA

Chief Financial Officer

Anna Gourd, General Counsel

Anna Gourd

General Counsel

Stuart Devine, Chief Commercial Officer

Stuart Devine

Chief Commercial Officer

Emily Barrett, Chief People Officer

Emily Barrett

Chief People Officer

Board of Directors

Dr John Gonzalez

Chairman

Eric Mayes, PhD

CEO

John Brimacombe

Operating Partner at Sussex Place Ventures and Senior Director, GM – Linguamatics, an IQVIA company

David Cummings

Partner at Molten Ventures

Peter Keen

Non-Executive Director